Meeting
2022 ASCO Annual Meeting
A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).
Authors
A. Dimitrios Colevas
Stanford Cancer Institute, Stanford, CA
A. Dimitrios Colevas , Lillian L. Siu , Darren Wan-Teck Lim , Bo Gao , Lisa Rojkjaer , Afton Katkov , Yisrael Katz , Brigette Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05166577
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6107)
DOI
10.1200/JCO.2022.40.16_suppl.TPS6107
Abstract #
TPS6107
Poster Bd #
93b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
First Author: Qin Xu
Poster
2019 ASCO Annual Meeting
Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).
First Author: Lillian L. Siu
Poster
2017 ASCO Annual Meeting
An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.
First Author: Assuntina Gesualda Sacco
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang